Tag: non-small cell lung cancer (nsclc) market trends

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Non-Small Cell Lung Cancer (NSCLC) Market From 2025 To 2029?

The market size of non-small cell lung cancer (nsclc) has experienced rapid expansion in recent years. It is set to increase from $20.1 billion in 2024 to $22.14 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.1%. The growth observed in the historical period is a product of advancements in immunotherapy, genomic profiling, and precision medicine, the extension of clinical trials, as well as initiatives aimed at smoking cessation.

The market size for non-small cell lung cancer (nsclc) is anticipated to experience a significant increase in the coming years. The value is predicted to reach$32.88 billion” by 2029, with a compound annual growth rate (CAGR) of 10.4%. The surge during the forecast period can be associated with the development of new combination therapies, the use of artificial intelligence (AI), advancements in personalized vaccines, international research collaborations, and patient-focused care. The forecast period will also witness major trends like the incorporation of telemedicine in the field of oncology, adoption of liquid biopsy technologies, progress in diagnostic technologies, a surge in minimally invasive surgery methods, and the usage of immune checkpoint inhibitors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Non-Small Cell Lung Cancer (NSCLC) Market?

The growing trend of tobacco usage is predicted to drive the expansion of the non-small cell lung cancer (NSCLC) market. When individuals utilise tobacco products through habits such as smoking, chewing, or snuffing, nicotine and several other chemicals are introduced into the body. This tobacco smoke is laden with carcinogens that can harm the deoxyribonucleic acid (DNA) found in lung cells, causing mutations and uncontrolled proliferation of cancerous cells, including those of non-small-cell lung cancer (NSCLC). For example, the 2024 National Youth Tobacco Survey released in October 2024 by the US Food and Drug Administration (USFDA), a US federal agency, reported that 1.1% of all students (roughly 2.25 million) were using tobacco products currently. Furthermore, 10.1% of high school students (around 1.58 million) and 5.4% of middle school students (roughly 640,000) were also current tobacco users. In addition, about 760,000 students (or 2.8%) reported current use of any combustible tobacco product, and approximately 840,000 (or 3.0%) admitted to using multiple tobacco products. Hence, this uptrend in tobacco consumption is propelling the non-small cell lung cancer (NSCLC) market’s growth.

Which Primary Segments of the Non-Small Cell Lung Cancer (NSCLC) Market Are Driving Growth and Industry Transformations?

The non-small cell lung cancer (nsclc)market covered in this report is segmented –

1) By Type: Squamous Cell Carcinoma; Large Cell Carcinoma; Adenocarcinoma; Other Types

2) By Therapy: Radiotherapy; Laserthearpy; Photodynamic Therapy (PDT); Other Therapies

3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Other Distribution Channels

Subsegments:

1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma; Non-Keratinizing Squamous Cell Carcinoma

2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma; Large Cell Neuroendocrine Carcinoma

3) By Adenocarcinoma: Invasive Adenocarcinoma; Bronchioloalveolar Carcinoma

4) By Other Types: Mixed Cell Type Carcinoma; Sarcomatoid Carcinoma

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Non-Small Cell Lung Cancer (NSCLC) Market?# Market?

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Most Significant Market Trends in the Non-Small Cell Lung Cancer (NSCLC) Market?

Top firms in the non-small cell lung cancer (NSCLC) market are investing in the development of various treatments, including monotherapy options, to gain a competitive advantage. Monotherapy involves the use of a single drug or therapeutic approach for treating a disease or condition, circumventing the need for multiple interventional methods. For example, in June 2022, the Switzerland-based pharmaceutical corporation Novartis AG received endorsement from the Belgium-based governing entity, the European Commission (EC), for the usage of Tabrecta (capmatinib) in treating adult patients suffering from advanced NSCLC with METex14 skipping. This provides innovative targeted therapy for NSCLC patients in Europe with advanced stages of the disease and METex14 skipping mutations, following prior treatment. It currently stands as the more prevalent targeted treatment for advanced NSCLC caused by METex14 skipping mutations.

View the full report here:

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

What Parameters Are Used to Define the Non-Small Cell Lung Cancer (NSCLC) Market?

Non-small cell lung cancer (NSCLC) is a type of epithelial lung cancer that develops in the tissues of the lungs and is characterized by the abnormal growth of cells. It is primarily caused by long-term smoking, genetic mutations, air pollution, and secondhand smoke.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Growth Rate of the Non-Small Cell Lung Cancer (NSCLC) Market?#_x000D_

In recent times, the size of the non-small cell lung cancer (NSCLC) market has seen substantial growth. It is projected to expand from $20.1 billion in 2024 to $22.35 billion in 2025, yielding a compound annual growth rate (CAGR) of 11.1%. This significant growth during the historic period can be credited to the emergence of immunotherapy, advancements in genomic profiling and precision medicine, wide-scale clinical trials, and initiatives to stop smoking._x000D_

_x000D_

#What Growth Rate Is Forecasted for the Non-Small Cell Lung Cancer (NSCLC) Market by 2029?#_x000D_

The market size for non-small cell lung cancer (NSCLC) is predicted to experience significant expansion in the coming years, reaching a value of $33.29 billion by 2029 with a compound annual growth rate (CAGR) of 10.5%. This anticipated growth in the forecast period is largely due to factors such as the development of combination therapies, the incorporation of artificial intelligence (AI), the proliferation of personalized vaccines, global research collaborations, and a focus on patient-centric care. Trends observed during the forecast period are expected to include the involvement of telemedicine in oncology, advancements in liquid biopsy technologies, progress in diagnostic technologies, the use of minimally invasive surgical procedures, and the implementation of immune checkpoint inhibitors._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp_x000D_

_x000D_

#Which Key Companies Are Shaping the Future of the Non-Small Cell Lung Cancer (NSCLC) Market?#_x000D_

Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines_x000D_

_x000D_

#Which Factors Are Driving Demand in the Non-Small Cell Lung Cancer (NSCLC) Industry?#_x000D_

An anticipated rise in the use of tobacco products is set to fuel the expansion of the non-small cell lung cancer (NSCLC) market. It is notable that tobacco consumption which includes smoking, chewing, or snuffing introduces harmful substances such as nicotine and other chemicals into the human body. It is these substances in tobacco smoke that are known to cause damage to deoxyribonucleic acid (DNA) in lung cells, which in turn leads to genetic anomalies and the rampant growth of cancerous cells, including those of non-small cell lung cancer (NSCLC). To put this in context, in October 2024, the US Food and Drug Administration (USFDA) published the 2024 National Youth Tobacco Survey, revealing that a significant 1.1% of all students, approximately 2.25 million students reported current use of tobacco products. Further, the statistics showed 10.1% of high school students (around 1.58 million) and 5.4% of middle school students (about 640,000) were tobacco users. Adding to this, 2.8% of students (around 760,000) reported the current use of any tobacco product that can be ignited, while a slightly higher figure of 3.0% (or about 840,000) were reported as using multiple tobacco products. Lastly, such a growing rate of tobacco consumption is seen as a major driver in the growth of the non-small cell lung cancer (NSCLC) market. Rising levels of air pollution, known for causing harmful effects to health, are being linked to increased cases of Non-Small Cell Lung Cancer (NSCLC), and this is expected to stimulate growth within the NSCLC market. Air pollution comprises harmful substances, usually in gas or particle form, within the Earth’s atmosphere, and these have a detrimental impact on human health. This pollution increases the likelihood of non-small lung cancer by causing inflammation and damage to the DNA of the lung cells, prompting the formation of cancerous tumors. For instance, in June 2023, the World Health Organization recorded that air and household pollution were linked to 7 million premature deaths annually. Moreover, about 2.4 billion people are at risk from harmful household air pollution, which result from using polluting open fires for cooking, powered by kerosene, biomass, and coal. Adding to this concern, the World Bank estimated in September 2022 that health harm caused by air pollution would total around $8.1 trillion annually, equating to a significant 6.1% of global GDP. As such, rising air pollution levels are expected to drive growth in the non-small cell lung cancer (NSCLC) market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp_x000D_

_x000D_

#How Is the Non-Small Cell Lung Cancer (NSCLC) Market Segmented by Several Divisions?#_x000D_

The non-small cell lung cancer (NSCLC) market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types_x000D_

2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies_x000D_

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels_x000D_

_x000D_

Subsegments:_x000D_

1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma_x000D_

2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma_x000D_

3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma_x000D_

4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma_x000D_

_x000D_

#What are the Emerging Market Trends Driving the Growth of the Non-Small Cell Lung Cancer (NSCLC) Industry?#_x000D_

Significant business entities in the non-small cell lung cancer (NSCLC) sector are striving for a competitive advantage by focusing on the development of various treatment pathways, like monotherapy treatments. Monotherapy refers to the employment of a single drug or therapy for a medical condition, relying on only one method or therapeutic strategy instead of multiple combined interventions. For example, Novartis AG, a pharmaceutical firm based in Switzerland, was granted permission by the European Commission (EC), a governing entity in Belgium, for the utilization of Tabrecta (capmatinib) in June 2022. The approval was for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) bearing METex14 skipping mutations, who had already underwent previous treatment. This sanction offers a new targeted treatment alternative for patients afflicted with advanced NSCLC in Europe. The mutations responsible for MET exon 14 (METex14) skipping make it the most sought-after targeted treatment for advanced NSCLC._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report_x000D_

_x000D_

#Which Regions Are Driving Growth in the Non-Small Cell Lung Cancer (NSCLC) Market?#_x000D_

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the non-small cell lung cancer (nsclc) market, and how is it changing globally?_x000D_

2. Who are the major companies in the non-small cell lung cancer (nsclc) market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the non-small cell lung cancer (nsclc) market right now?_x000D_

4. Which products or customer segments are growing the most in the non-small cell lung cancer (nsclc) market?_x000D_

5. What factors are helping or slowing down the growth of the non-small cell lung cancer (nsclc) market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the non-small cell lung cancer (nsclc) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Non-Small Cell Lung Cancer (NSCLC) Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market scale for non-small cell lung cancer (NSCLC) has seen a swift upturn in the past few years. It is projected to escalate from $20.1 billion in 2024 to about $22.35 billion by 2025, boasting a compound annual growth rate (CAGR) of 11.1%. The enlargement of this market in the historic period is a result of the progress in immunotherapy, genomics profiling, precision medicine, the broadening of clinical trials, along with initiatives aim at stopping smoking.

Anticipated to experience swift expansion in the coming years, the non-small cell lung cancer (NSCLC) market has a projected worth of $33.29 billion in 2029, with a compound annual growth rate (CAGR) of 10.5%. Factors contributing to the growth during the forecast period include the adoption of combination therapies, the incorporation of artificial intelligence (AI), development of personalized vaccines, worldwide collaborative research efforts, and a focus on patient-centric care. Noteworthy trends projected for the forecast period incorporate the application of telemedicine in oncology, the introduction of liquid biopsy technologies, advancements in diagnostic techniques, the use of minimally invasive surgery methods, and the employment of immune checkpoint inhibitors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp

What Are the Core Growth Drivers Propelling the Non-Small Cell Lung Cancer (NSCLC) Market Forward?

The surge in tobacco usage is projected to drive the expansion of the non-small cell lung cancer (NSCLC) market. The reference to tobacco consumption pertains to the utilization of tobacco goods by individuals, largely through smoking, chewing, or snuffing, introducing nicotine and other chemicals into their system. A number of carcinogens present in tobacco smoke have the potential to harm the DNA in lung cells, which can result in mutations and unchecked growth of malignant cells, including non-small cell lung cancer (NSCLC). As an illustration, the US Food and Drug Administration (USFDA) in October 2024, reported in the 2024 National Youth Tobacco Survey that 1.1% of all students (roughly 2.25 million) were currently using tobacco products. This includes 10.1% of high school students (about 1.58 million) and 5.4% of middle school children (around 640,000); moreover, 2.8% of the students (about 760,000) confessed to current use of any combustible tobacco product, and 3.0% (approximately 840,000) admitted to using multiple tobacco products. Hence, the surging rate of tobacco usage is anticipated to drive the non-small cell lung cancer (NSCLC) market’s growth. Non-Small Cell Lung Cancer (NSCLC) Market Driver: Increased Instances of Non-Small Cell Lung Cancer (NSCLC) Linked to Growing Air Pollution Levels

What Segment Types Define the Non-Small Cell Lung Cancer (NSCLC) Market Structure?

The non-small cell lung cancer (NSCLC) market covered in this report is segmented –

1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types

2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels

Subsegments:

1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma

2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma

3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma

4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Non-Small Cell Lung Cancer (NSCLC) Market?

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Emerging Trends that Are Influencing theNon-Small Cell Lung Cancer (NSCLC) Industry Evolution?

Major corporations involved in the non-small cell lung cancer (NSCLC) marketplace are concentrating their efforts on generating various treatment methods, including monotherapy treatments, in the quest to establish a competitive advantage. A therapy like monotherapy heavily involves using only one treatment type or procedure for a medical condition, as opposed to an integration of various strategies. For example, Novartis AG, a pharmaceutical corporation located in Switzerland, was granted authorization by the European Commission (EC), a regulatory authority in Belgium, to use Tabrecta (capmatinib) for adult patients suffering from advanced non-small cell lung cancer with METex14 skipping in June 2022. This presents a fresh targeted therapy option for European patients previously treated for advanced non-small cell lung cancer (NSCLC) containing mutations triggering MET exon 14 (METex14) skipping. It is currently the foremost targeted therapy for advanced NSCLC with variations that lead to METex14 skipping.

View the full report here:

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

What Is the Definition of the Non-Small Cell Lung Cancer (NSCLC) Market?

Non-small cell lung cancer (NSCLC) is a type of epithelial lung cancer that develops in the tissues of the lungs and is characterized by the abnormal growth of cells. It is primarily caused by long-term smoking, genetic mutations, air pollution, and secondhand smoke.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of theNon-Small Cell Lung Cancer (NSCLC) Market from 2025 to 2034?

The non-small cell lung cancer (NSCLC) market is anticipated to grow due to the rising prevalence of tobacco use. In an average person, use of tobacco usually entails smoking, chewing, or snuffing tobacco products, all of which introduce harmful substances like nicotine into the body. Lung cells exposed to tobacco smoke, which carries numerous carcinogens, can sustain DNA damage that cause mutations and unregulated growth of cancerous cells, a characteristic of NSCLC. The 2024 National Youth Tobacco Survey, published by the US Food and Drug Administration (USFDA) in October 2024, revealed that about 2.25 million (1.1%) students were active tobacco users, including 1.58 million (10.1%) high school students and around 640,000 (5.4%) middle school students. Also, about 760,000 (2.8%) students reported current use of combustible products; an estimated 840,000 (3.0%) admitted to using multiple tobacco products. Given these statistics, the growth of the non-small cell lung cancer (NSCLC) market is likely being fueled by the escalating tobacco use. Moving to the next factor, escalating levels of air pollution are poised to boost the non-small cell lung cancer (NSCLC) market. Toxic substance releases into the earth’s atmosphere, whether in forms such as gases or particles, result in air pollution that negatively impacts human health. Elevated risk of NSCLC can be linked to exposure to air pollution, which can trigger inflammation, damage DNA and cause lung cell mutations, culminating in cancerous growths. Data from the Switzerland-based World Health Organization in June 2023 suggested that 7 million premature deaths annually were associated with ambient and household air pollution. Furthermore, around 2.4 billion people are exposed to perilous levels of domestic air pollution due to the use of unclean combustion materials like coal, kerosene, and biomass for cooking. In September 2022, the World Bank, an American financial establishment, stated that health damages attributed to air pollution would reach about $8.1 trillion annually, equivalent to 6.1% of worldwide GDP. Given these statistics, the steady surge of air pollution makes it another significant factor propelling the growth of the non-small cell lung cancer (NSCLC) market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp

#How Does the ProjectedNon-Small Cell Lung Cancer (NSCLC) Market Growth Compare Over the Forecast Period?

The market for non-small cell lung cancer (NSCLC) has witnessed a significant expansion lately. It is projected to escalate from $20.1 billion in 2024 to $22.35 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.1%. Factors contributing to the growth of this market during the previous period are the advancements in immunotherapy, genomic profiling, precision medicine, enlargement of clinical trials and smoking cessation initiatives.

In the coming years, there’s expected to escalate growth in the non-small cell lung cancer (NSCLC) market. This market is projected to hike up to $33.29 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 10.5%. The development during the forecast timeline can be credited to the introduction of combination therapies, the application of artificial intelligence (AI), the broadening of personalized vaccines, international research partnerships, and patient-focused care. In the prediction period, predominant trends will encompass the inclusion of telemedicine in oncology, liquid biopsy technologies, advancements in diagnostic technologies, adoption of minimally invasive surgical methods, and immune checkpoint inhibitors.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232

How Are Market Trends and Innovations Revolutionizing theNon-Small Cell Lung Cancer (NSCLC) Industry in Recent Times?

Leading firms in the non-small cell lung cancer (NSCLC) market are concentrating on developing diverse treatment options such as monotherapy treatments to gain a competitive advantage. Monotherapy treatment implies employing a single drug or therapy for treating a medical condition or disorder instead of using a mix of various approaches. For example, in June 2022, Swiss pharmaceutical firm Novartis AG received a green light from the European Commission (EC), a governance body based in Belgium, for its product Tabrecta (capmatinib) aimed at treating adult patients diagnosed with advanced non-small cell lung cancer with METex14 skipping. This provides a cutting-edge targeted therapeutic option for European patients who have undergone previous treatment and have advanced non-small cell lung cancer (NSCLC) with mutations leading to MET exon 14 (METex14) skipping. This is currently the most favored targeted treatment for advanced NSCLC that comes with changes leading to METex14 skipping.

Which Key Market Players Are Shaping the Future and Growth of theNon-Small Cell Lung Cancer (NSCLC) Market?

Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

What Are the Core Segments of the Non-Small Cell Lung Cancer (NSCLC) Market, and How Do They Contribute to Growth?

The non-small cell lung cancer (NSCLC) market covered in this report is segmented –

1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types

2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels

Subsegments:

1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma

2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma

3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma

4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp

What Regions Are Dominating the Non-Small Cell Lung Cancer (NSCLC) Market Growth?

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Non-Small Cell Lung Cancer (NSCLC) Market 2025, By The Business Research Company:

Urinary Tract Cancer Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report

Small Cell Lung Cancer Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Bridges, Gateways And Routers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bridges-gateways-and-routers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the non-small cell lung cancer (nsclc) market grown over the years?

The non-small cell lung cancer (NSCLC) market has experienced rapid growth and is projected to rise from $20.1 billion in 2024 to $22.35 billion in 2025 at a CAGR of 11.1%. Growth in the past period was driven by advancements in immunotherapy, genomic profiling, precision medicine, expanded clinical trials, and smoking cessation initiatives.

What Is the forecasted market size and growth rate for the non-small cell lung cancer (nsclc) market?

The non-small cell lung cancer (NSCLC) market is set for significant growth, reaching $33.29 billion in 2029 at a CAGR of 10.5%. Growth drivers include emerging combination therapies, AI integration, expansion of personalized vaccines, global research collaborations, and patient-centered care. Notable trends include telemedicine in oncology, liquid biopsy technologies, diagnostic advancements, minimally invasive surgical techniques, and immune checkpoint inhibitors.

Get your non-small cell lung cancer (nsclc) market report here!

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

What are the major factors driving growth in the non-small cell lung cancer (nsclc) market?

The rising tobacco consumption rate is projected to accelerate the growth of the non-small cell lung cancer (NSCLC) market. Tobacco use, whether through smoking, chewing, or snuffing, exposes individuals to nicotine and harmful chemicals that can lead to lung cell mutations and cancer development. For instance, the 2024 National Youth Tobacco Survey released by the US Food and Drug Administration (USFDA) in October 2024 found that 1.1% of all students—approximately 2.25 million—used tobacco products, with 10.1% of high school students (around 1.58 million) and 5.4% of middle school students (about 640,000) reporting tobacco use. Additionally, 2.8% (about 760,000) used combustible tobacco products, while 3.0% (approximately 840,000) consumed multiple tobacco products. As a result, the increasing prevalence of tobacco consumption is contributing to the growth of the NSCLC market.

What key areas define the segmentation of the global non-small cell lung cancer (nsclc) Market?

The non-small cell lung cancer (NSCLC) market covered in this report is segmented –

1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types

2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels

Subsegments:

1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma

2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma

3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma

4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp

What are the top market players propelling the growth of the non-small cell lung cancer (nsclc) industry?

Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines

What are the key trends shaping the future of the non-small cell lung cancer (nsclc) market?

Leading companies in the non-small cell lung cancer (NSCLC) market are concentrating on the development of a variety of treatment alternatives, including monotherapy interventions, to establish a competitive advantage. The concept of monotherapy treatment refers to the utilization of a single medication or therapeutic approach for treating a medical condition or disorder, as opposed to using a combination of different strategies. For example, in June 2022, the European Commission, a Belgium-based regulatory body, granted approval to Novartis AG, a Swiss pharmaceutical company, for the use of Tabrecta (capmatinib) in the treatment of adult patients with advanced non-small cell lung cancer exhibiting METex14 skipping. This drug provides a new targeted treatment option for those patients in Europe who have previously undergone treatments and are suffering from advanced NSCLC with METex14 skipping-causing mutations. This is currently the most favored targeted therapy for advanced NSCLC with METex14 skipping-causing alterations.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232

What regions are dominating the non-small cell lung cancer (nsclc) market growth?

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Urinary Tract Cancer Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report

Small Cell Lung Cancer Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Bridges, Gateways And Routers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bridges-gateways-and-routers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Growth Potential of the Non-Small Cell Lung Cancer (NSCLC) Market, and How Will It Perform by 2034?

In recent years, the market size for non-small cell lung cancer (NSCLC) has seen rapid expansion. The growth, set to increase from $20.1 billion in 2024 to $22.35 billion in 2025, registers a compound annual growth rate (CAGR) of 11.1%. Various factors responsible for the growth in the past include the development of immunotherapy, expansion of clinical trials, and initiatives to stop smoking, along with the advancement in genomic profiling and precision medicine.

Expectations reveal that the market size for non-small cell lung cancer (NSCLC) is on the verge of robust expansion in the coming years, expected to surge to $33.29 billion by 2029, with a compound annual growth rate (CAGR) of 10.5%. The growth anticipated in the forecast period can be pegged on the advent of combination therapies, the assimilation of artificial intelligence (AI), the development of personalized vaccines, collective global research efforts, and a focus on patient-centric care. Also, the forecast period will be characterized by significant trends, such as the incorporation of telemedicine in oncology, upcoming liquid biopsy technologies, improvements in diagnostic technology, the implementation of minimally invasive surgical approaches, and the use of immune checkpoint inhibitors.

What Combination of Drivers Is Leading to Accelerated Growth in the Non-Small Cell Lung Cancer (NSCLC) Market?

The non-small cell lung cancer (NSCLC) market’s growth is predicted to be bolstered by growing tobacco use. Tobacco use is characterized by the personal consumption of tobacco goods in various forms – smoking, chewing, or snuffing – introducing nicotine and other chemicals into the human system. These tobacco-derived carcinogens can harm the DNA in lung cells, causing mutations and uncontrolled proliferation of cancerous cells, including NSCLC. According to the 2024 National Youth Tobacco Survey released by the US Food and Drug Administration in October 2024, roughly 2.25 million students (1.1%) currently use tobacco. This includes about 1.58 million high school students (10.1%) and around 640,000 middle school students (5.4%), with about 760,000 students (2.8%) currently using any combustible tobacco product and approximately 840,000 (3.0%) using multiple tobacco products. Hence, the growing tobacco consumption rate is steering the expansion of the non-small cell lung cancer (NSCLC) market. The proliferation of the non-small cell lung cancer (NSCLC) market is projected to be further fueled by escalating levels of air pollution. Air pollution involves detrimental substances, primarily in the form of gases or particles present in the Earth’s atmosphere, eliciting adverse health impacts. These pollutants can boost the risk of NSCLC by inducing inflammation, DNA damage, and mutations in lung cells, giving rise to cancerous tumors. For instance, the World Health Organization, in June 2023, linked air and household pollution to about 7 million early deaths each year. In addition, nearly 2.4 billion individuals are exposed to hazardous household air pollution levels while using contaminating open fires for cooking, powered by kerosene, biomass, and coal. Furthermore, the World Bank, a US-based financial institution, predicted in September 2022 that health damage caused by air pollution would approximate $8.1 trillion annually, equivalent to 6.1% of global GDP. Consequently, the surge in air pollution levels is poised to accelerate the growth of the non-small cell lung cancer (NSCLC) market.

Explore Comprehensive Insights Into The Global Non-Small Cell Lung Cancer (NSCLC) Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp

Who Are the Major Companies Shaping the Competitive Landscape of the Non-Small Cell Lung Cancer (NSCLC) Market?

Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines

What Are the Key Emerging Trends in the Non-Small Cell Lung Cancer (NSCLC) Market for the Next Decade?

Leading companies in the non-small cell lung cancer (NSCLC) market are concentrating on the development of a variety of treatment alternatives, including monotherapy interventions, to establish a competitive advantage. The concept of monotherapy treatment refers to the utilization of a single medication or therapeutic approach for treating a medical condition or disorder, as opposed to using a combination of different strategies. For example, in June 2022, the European Commission, a Belgium-based regulatory body, granted approval to Novartis AG, a Swiss pharmaceutical company, for the use of Tabrecta (capmatinib) in the treatment of adult patients with advanced non-small cell lung cancer exhibiting METex14 skipping. This drug provides a new targeted treatment option for those patients in Europe who have previously undergone treatments and are suffering from advanced NSCLC with METex14 skipping-causing mutations. This is currently the most favored targeted therapy for advanced NSCLC with METex14 skipping-causing alterations.

Secure Your Global Non-Small Cell Lung Cancer (NSCLC) Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

What Major Market Segments Define the Scope and Growth of the Non-Small Cell Lung Cancer (NSCLC) Market?

The non-small cell lung cancer (NSCLC) market covered in this report is segmented –

1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types

2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels

Subsegments:

1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma

2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma

3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma

4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma

Which Regions Are Making a Mark in the Non-Small Cell Lung Cancer (NSCLC) Market Growth?

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Does the Definition of the Non-Small Cell Lung Cancer (NSCLC) Market Include?

Non-small cell lung cancer (NSCLC) is a type of epithelial lung cancer that develops in the tissues of the lungs and is characterized by the abnormal growth of cells. It is primarily caused by long-term smoking, genetic mutations, air pollution, and secondhand smoke.

Browse Through More Similar Reports By The Business Research Company:

Urinary Tract Cancer Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report

Small Cell Lung Cancer Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Bridges, Gateways And Routers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bridges-gateways-and-routers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: